Debiopharm S.A.

The market for targeted radiotherapy in oncology could soon become a bit more competitive as ITM Isotope Technologies Munich unveiled topline Phase III results for ITM-11 (non-carrier-added 177 Lu-edo

In late October 2024, the first patient in a trial of Ariceum’s radioligand therapy (RLT) for glioblastoma, an aggressive brain cancer, showed 50% tumor shrinkage after just four to six weeks of tre

The radiopharmaceutical space saw a couple of huge deals at the end of last year, and another flurry, albeit on a rather smaller scale, happened this week. On September 12, both Sanofi and ITM Isot

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Helsinn Extends Akynzeo Marketing